Prognostic impact of 6 min walk test distance in patients with systolic heart failure : insights from the WARCEF trial
© 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology..
AIMS: This study aimed to investigate the impact of baseline 6 min walk test distance (6MWTD) on time to major cardiovascular (CV) events in heart failure with reduced ejection fraction (HFrEF) and its impact in clinically relevant subgroups.
METHODS AND RESULTS: In the WARCEF (Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction) trial, 6MWTD at baseline was available in 2102 HFrEF patients. Median follow-up was 3.4 years. All-cause death and heart failure hospitalization (HFH) exhibited a significant non-linear relationship with 6MWTD (P = 0.023 and 0.032, respectively), whereas a significant association between 6MWTD and CV death was shown in a linear model [hazard ratio (HR) per 10 m increase, 0.989; P = 0.011]. In linear splines with the best cut-off point at 200 m, the positive effect of a longer 6MWTD on all-cause death and HFH was only observed for 6MWTD > 200 m (HR per 10 m increase, 0.987; P = 0.0036 and 0.986; P = 0.0022, respectively). The associations between 6MWTD and CV outcomes were consistent across clinical subgroups; for age, a significant relationship between 6MWTD and HFH was observed in patients ≥60 years (HR per 10 m increase, 0.98; P < 0.001), but not in patients <60 years (HR per 10 m increase, 1.00; P = 0.98; P = 0.02 for the interaction).
CONCLUSIONS: In HFrEF, 6MWTD is independently associated with all-cause death, CV death, and HFH. 6MWTD of 200 m is the best cut-off point for predicting these adverse events. The prognostic impact of 6MWTD for HFH was only observed in older patients.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2021 |
---|---|
Erschienen: |
2021 |
Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
---|---|
Enthalten in: |
ESC heart failure - 8(2021), 2 vom: 18. Apr., Seite 819-828 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Matsumoto, Kenji [VerfasserIn] |
---|
Links: |
---|
Themen: |
5Q7ZVV76EI |
---|
Anmerkungen: |
Date Completed 01.07.2021 Date Revised 01.07.2021 published: Print-Electronic Citation Status MEDLINE |
---|
doi: |
10.1002/ehf2.13068 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM319417646 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM319417646 | ||
003 | DE-627 | ||
005 | 20231225171413.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2021 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1002/ehf2.13068 |2 doi | |
028 | 5 | 2 | |a pubmed24n1064.xml |
035 | |a (DE-627)NLM319417646 | ||
035 | |a (NLM)33377631 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Matsumoto, Kenji |e verfasserin |4 aut | |
245 | 1 | 0 | |a Prognostic impact of 6 min walk test distance in patients with systolic heart failure |b insights from the WARCEF trial |
264 | 1 | |c 2021 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 01.07.2021 | ||
500 | |a Date Revised 01.07.2021 | ||
500 | |a published: Print-Electronic | ||
500 | |a Citation Status MEDLINE | ||
520 | |a © 2020 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on behalf of the European Society of Cardiology. | ||
520 | |a AIMS: This study aimed to investigate the impact of baseline 6 min walk test distance (6MWTD) on time to major cardiovascular (CV) events in heart failure with reduced ejection fraction (HFrEF) and its impact in clinically relevant subgroups | ||
520 | |a METHODS AND RESULTS: In the WARCEF (Warfarin versus Aspirin in Reduced Cardiac Ejection Fraction) trial, 6MWTD at baseline was available in 2102 HFrEF patients. Median follow-up was 3.4 years. All-cause death and heart failure hospitalization (HFH) exhibited a significant non-linear relationship with 6MWTD (P = 0.023 and 0.032, respectively), whereas a significant association between 6MWTD and CV death was shown in a linear model [hazard ratio (HR) per 10 m increase, 0.989; P = 0.011]. In linear splines with the best cut-off point at 200 m, the positive effect of a longer 6MWTD on all-cause death and HFH was only observed for 6MWTD > 200 m (HR per 10 m increase, 0.987; P = 0.0036 and 0.986; P = 0.0022, respectively). The associations between 6MWTD and CV outcomes were consistent across clinical subgroups; for age, a significant relationship between 6MWTD and HFH was observed in patients ≥60 years (HR per 10 m increase, 0.98; P < 0.001), but not in patients <60 years (HR per 10 m increase, 1.00; P = 0.98; P = 0.02 for the interaction) | ||
520 | |a CONCLUSIONS: In HFrEF, 6MWTD is independently associated with all-cause death, CV death, and HFH. 6MWTD of 200 m is the best cut-off point for predicting these adverse events. The prognostic impact of 6MWTD for HFH was only observed in older patients | ||
650 | 4 | |a Journal Article | |
650 | 4 | |a Research Support, N.I.H., Extramural | |
650 | 4 | |a 6 min walk test | |
650 | 4 | |a Cardiovascular event | |
650 | 4 | |a Heart failure | |
650 | 4 | |a Prognosis | |
650 | 7 | |a Warfarin |2 NLM | |
650 | 7 | |a 5Q7ZVV76EI |2 NLM | |
700 | 1 | |a Xiao, Yi |e verfasserin |4 aut | |
700 | 1 | |a Homma, Shunichi |e verfasserin |4 aut | |
700 | 1 | |a Thompson, John L P |e verfasserin |4 aut | |
700 | 1 | |a Buchsbaum, Richard |e verfasserin |4 aut | |
700 | 1 | |a Ito, Kazato |e verfasserin |4 aut | |
700 | 1 | |a Anker, Stefan D |e verfasserin |4 aut | |
700 | 1 | |a Qian, Min |e verfasserin |4 aut | |
700 | 1 | |a Di Tullio, Marco R |e verfasserin |4 aut | |
700 | 0 | |a WARCEF Investigators |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t ESC heart failure |d 2014 |g 8(2021), 2 vom: 18. Apr., Seite 819-828 |w (DE-627)NLM261791397 |x 2055-5822 |7 nnns |
773 | 1 | 8 | |g volume:8 |g year:2021 |g number:2 |g day:18 |g month:04 |g pages:819-828 |
856 | 4 | 0 | |u http://dx.doi.org/10.1002/ehf2.13068 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 8 |j 2021 |e 2 |b 18 |c 04 |h 819-828 |